Evidence map›Paper›PMID 36029653›Full record

Trial reportESMO open2022

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF

J Tabernero, A Grothey, D Arnold, A de Gramont, M Ducreux, P O'Dwyer, A Tahiri, F Gilberg, N Irahara, H-J Schmoll and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06930118 (An Exploratory Study Investigating the Combination of Chidamide, Regorafenib, Plus Iparomlimab and Tuvonralimab for the Treatment of Drug-esistant and Efractory Dvanced Colorectal Cancer), which is not on this map. Cited by 29 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 7 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06930118 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

An Exploratory Study Investigating the Combination of Chidamide, Regorafenib, Plus Iparomlimab and Tuvonralimab for the Treatment of Drug-esistant and Efractory Dvanced Colorectal Cancer

TypeinterventionalSponsorShanghai Changzheng HospitalRan2025 to 2027Enrolled60ConditionsAdvanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal CancerArmschidamide, regorafenib, and iparomlimab/tuvonralimab
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. The Current Role of Antiangiogenics in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 6 countries.

J TaberneroVall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain. Electronic address: jtabernero@vhio.net.
A GrotheyWest Cancer Center, Germantown, USA.
D ArnoldAsklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany.
A de GramontFranco-British Hospital, Levallois-Perret, France.
M DucreuxGustave Roussy, Université Paris Saclay, Villejuif, France.
P O'DwyerAbramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
A TahiriF. Hoffmann-La Roche Ltd, Basel, Switzerland.
F GilbergF. Hoffmann-La Roche Ltd, Basel, Switzerland.
N IraharaF. Hoffmann-La Roche Ltd, Basel, Switzerland.
H-J SchmollMartin-Luther-University, Halle, Germany.
E Van CutsemUniversity Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium.
Roche (Switzerland) · CHAsklepios Klinik Altona · DEInstitut Hospitalier Franco Britannique · FRKU Leuven · BEMartin Luther University Halle-Wittenberg · DEUniversitat de Vic - Universitat Central de Catalunya · ESUniversité Paris-Saclay · FRUniversity of Pennsylvania · USWest Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMODUL is an adaptable, signal-seeking trial designed to test novel agents in predefined patient subgroups in first-line metastatic colorectal cancer (mCRC). PATIENTS AND

methodsPatients with measurable, unresectable, previously untreated mCRC received induction with ≤8 cycles of FOLFOX + bevacizumab followed by randomization to maintenance treatment comprising control [fluoropyrimidine (FP)/bevacizumab: 5-fluorouracil 1600-2400 mg/m

resultsFour hundred and forty-five patients with BRAF

conclusionsAdding atezolizumab to FP/bevacizumab as first-line maintenance treatment after FOLFOX + bevacizumab induction for BRAF

Indexed as

Colonic NeoplasmsColorectal NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCapecitabineFluorouracilHumansIntestine, LargeLeucovorinProto-Oncogene Proteins B-rafAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabBRAF protein, humanCapecitabineFluorouracilLeucovorinProto-Oncogene Proteins B-rafatezolizumabbevacizumabmetastatic colorectal cancerPD-L1

Identifiers

PMID36029653
PMCPMC9588902
OpenAlexW4293200724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.